Indications: Osteoporosis

Description:

1. Class 1 new drugs for therapeutic biological products. For the treatment of osteoporosis.

2. The drug can significantly improve bone mineral density and bone resistance through bone assimilation, so as to reduce the incidence of fracture and treat the root cause.

3. In 2011, the project was transferred to a domestic pharmaceutical enterprise after completing clinical phase I; Phase III clinical research will be completed and industrialization will be realized.